FDA Releases Report on Transparency to Regulated Industry: Not Much To See Here
This article was originally published in RPM Report
Executive Summary
The third phase of the Food & Drug Administration’s Transparency Initiative lists 19 ways that the agency plans to improve transparency to the industries it regulates. FDA is also seeking comments on five proposed steps. Unlike earlier phases, there isn’t too much to see here.
You may also be interested in...
CDER Advisory Committee Staffing Improves, But Trouble Spots Remain
After years of widespread vacancies on advisory committees, the Food & Drug Administration appears to have tackled most of the problems. But there are a couple of significant outliers, most significantly the Dermatology & Ophthalmic Products Advisory Committee. Will changes in conflict of interest rules and a new recruitment effort help FDA find and retain advisory committee members?
Lessons Learned: How Avandia is Changing the Way FDA Does Business
FDA learned two important lessons from the Avandia debacle. First, the agency needs to be a better communicator—which means telling the public more about what it knows (and doesn’t know) about the safety of marketed products. But Avandia is also leading the agency to rethink what should be required to demonstrate safety, especially for chronic care therapies. Both could mean big changes for industry.
Lessons Learned: How Avandia is Changing the Way FDA Does Business
FDA learned two important lessons from the Avandia debacle. First, the agency needs to be a better communicator—which means telling the public more about what it knows (and doesn’t know) about the safety of marketed products. But Avandia is also leading the agency to rethink what should be required to demonstrate safety, especially for chronic care therapies. Both could mean big changes for industry.